CR20190096A - Análogos de insulina - Google Patents

Análogos de insulina

Info

Publication number
CR20190096A
CR20190096A CR20190096A CR20190096A CR20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A
Authority
CR
Costa Rica
Prior art keywords
insulin
present
insulin analogues
relates
methods
Prior art date
Application number
CR20190096A
Other languages
English (en)
Inventor
Michael Colin Lawrence
Danny Hung Chieh Chou
Oliviera M Baldomero
John Gerbrant Tasman Menting
Brian Smith
Helena Safavi-Hemami
Original Assignee
Walter & Eliza Hall Inst Medical Res
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Walter & Eliza Hall Inst Medical Res, Univ Utah Res Found filed Critical Walter & Eliza Hall Inst Medical Res
Priority claimed from PCT/AU2017/050758 external-priority patent/WO2018014091A1/en
Publication of CR20190096A publication Critical patent/CR20190096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)

Abstract

La presente invención se refiere particularmente a análogos de insulina que tienen cadenas B cortas. La presente invención también se refiere a la estructura cristal de insulina del veneno de caracoles cono y a métodos para utilizar el cristal, así como información estructural relacionada para cribar y diseñar análogos de insulina que interactúen o modelen el receptor de insulina. La presente invención también se refiere a métodos terapéuticos y profilácticos utilizando análogos de insulina.
CR20190096A 2016-07-22 2017-07-21 Análogos de insulina CR20190096A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
US201762483118P 2017-04-07 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (en) 2016-07-22 2017-07-21 Insulin analogs

Publications (1)

Publication Number Publication Date
CR20190096A true CR20190096A (es) 2019-09-16

Family

ID=65524551

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190096A CR20190096A (es) 2016-07-22 2017-07-21 Análogos de insulina

Country Status (15)

Country Link
US (2) US11248034B2 (es)
EP (1) EP3487876A4 (es)
JP (2) JP7143275B2 (es)
KR (2) KR20230070049A (es)
CN (2) CN116874584A (es)
AU (1) AU2021269301B2 (es)
BR (1) BR112019000991A2 (es)
CL (1) CL2019000159A1 (es)
CR (1) CR20190096A (es)
IL (1) IL264330B2 (es)
MA (1) MA45727A (es)
MX (1) MX2019000829A (es)
RU (1) RU2769476C2 (es)
SG (1) SG11201900181RA (es)
ZA (1) ZA201901095B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190096A (es) 2016-07-22 2019-09-16 Walter & Eliza Hall Inst Medical Res Análogos de insulina
CN109803679A (zh) * 2016-08-30 2019-05-24 得克萨斯州大学系统董事会 在基因组重新编码生物体中生产硒代生物制剂
WO2023229624A1 (en) * 2022-05-26 2023-11-30 Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) Transdermal insulin formulations and methods of use thereof
JP7838098B2 (ja) 2022-05-31 2026-03-31 エルジー エナジー ソリューション リミテッド 高分子固体電解質及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104305C1 (ru) 1986-08-29 1998-02-10 Ново Нордиск А.С. Аналоги инсулина человека, способ их получения, раствор для инъекций
WO2005095443A1 (ja) * 2004-03-31 2005-10-13 Cardio Incorporated ペプチド改変を利用したドラッグデリバリーシステム
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP5710253B2 (ja) * 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
US9200053B2 (en) * 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2012511506A (ja) 2008-12-09 2012-05-24 ノヴォ・ノルディスク・アー／エス 新規インスリンアナログ
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
JP5890516B2 (ja) * 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
BR112015023672A2 (pt) * 2013-03-15 2017-07-18 Univ Case Western Reserve análogo de insulina, orto-fluoro, sequência de dna codificando a cadeia a de análogo de insulina, sequência de dna codificando a cadeia b de análogo de insulina e uso de um análogo de insulina.
CA2915354A1 (en) * 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs
CR20190096A (es) 2016-07-22 2019-09-16 Walter & Eliza Hall Inst Medical Res Análogos de insulina
US20220389073A1 (en) * 2019-10-24 2022-12-08 University Of Utah Research Foundation Novel Mini-Insulin With Extended C-Terminal A Chain

Also Published As

Publication number Publication date
IL264330A (es) 2019-03-31
US20220340636A1 (en) 2022-10-27
JP7143275B2 (ja) 2022-09-28
JP2022191233A (ja) 2022-12-27
KR20190039719A (ko) 2019-04-15
AU2021269301A1 (en) 2021-12-09
RU2019100497A (ru) 2020-08-24
CN116874584A (zh) 2023-10-13
RU2769476C2 (ru) 2022-04-01
RU2019100497A3 (es) 2021-05-11
NZ750355A (en) 2023-10-27
JP2019534843A (ja) 2019-12-05
CL2019000159A1 (es) 2019-08-16
IL264330B2 (en) 2024-05-01
AU2021269301B2 (en) 2023-12-21
EP3487876A1 (en) 2019-05-29
US12410228B2 (en) 2025-09-09
US20190241640A1 (en) 2019-08-08
EP3487876A4 (en) 2020-02-19
US11248034B2 (en) 2022-02-15
SG11201900181RA (en) 2019-02-27
CN110072884A (zh) 2019-07-30
MA45727A (fr) 2019-05-29
CN110072884B (zh) 2023-07-28
KR20230070049A (ko) 2023-05-19
KR102529353B1 (ko) 2023-05-04
BR112019000991A2 (pt) 2019-07-02
MX2019000829A (es) 2019-08-29
IL264330B1 (en) 2024-01-01
ZA201901095B (en) 2022-04-28

Similar Documents

Publication Publication Date Title
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2016004461A (es) Analogos de glucagon acilados.
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
CL2016000908A1 (es) Métodos para el tratamiento de afecciones asociados a la activación del complemento dependiente de masp-2 declaración relacionada con el listado de secuencias
EA201691911A1 (ru) Быстродействующие композиции инсулина
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
MX384292B (es) Metodos utiles en la sintesis de analogos de halicondrina b.
MX2020001835A (es) Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
UY36870A (es) Análogos de insulina novedosos
MX2022013454A (es) Moduladores de la actividad del complemento.
MX2016015630A (es) Nuevos compuestos.
MX378186B (es) Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
MX378108B (es) Anticuerpos anti-met y composiciones.
CR20190096A (es) Análogos de insulina
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006567A (es) Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
CO2017005404A2 (es) Anticuerpos contra il-6
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CR20160448A (es) Nuevos derivados de piridina
CL2020000310A1 (es) Análogos de insulina acilados novedosos y usos de estos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1